Atrial Fibrillation Association

Study Published in JAMA Cardiology Finds Zio by iRhythm Proactively Identifies Atrial Fibrillation, Increases Detection Tenfold

Retrieved on: 
Wednesday, February 24, 2021
Cardiac electrophysiology, Cardiac arrhythmia, Branches of biology, Physiology, Atrial fibrillation, Cardiovascular system, Cardiac monitoring, Atrial Fibrillation Association, Palpitations

The transatlantic clinical trial found that Zio by iRhythm , an ambulatory cardiac monitoring solution, led to a tenfold increase in the detection of atrial fibrillation (AF) versus patients receiving standard clinical care.

Key Points: 
  • The transatlantic clinical trial found that Zio by iRhythm , an ambulatory cardiac monitoring solution, led to a tenfold increase in the detection of atrial fibrillation (AF) versus patients receiving standard clinical care.
  • The study results lend support for Zio as a screening tool for early detection of AF.
  • iRhythm is a leading digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed.
  • The company believes improvements in arrhythmia detection and characterization have the potential to change the clinical management of patients.